NITTO DENKO AND ISIS PHARMACEUTICALS ANNOUNCE HIGH-PERFORMANCE CROSS-LINKED POLYSTYRENE BEAD

Nitto Denko and Nitto Denko Technical, a dedicated R&D facility in Oceanside, Calif., have announced development of a high-performance cross-linked polystyrene bead which can support a high-grade, high-yield synthesis of oligonucleotides, essential to DNA and RNA-based gene therapies, and provide solid support for the synthesis of antisense drugs. The development was achieved in a joint venture with Isis Pharmaceuticals, a U.S. company that was the first in the world to succeed in bringing an antisense drug (a gene-repair therapy) to market.

Japan Corporate News (http://www.japancorp.net/Article.Asp?Art_ID=9112)